Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics

Kairos Pharma, LTD.

Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).
Consideration includes 16.5% of Kairos shares on fully diluted basis, $15M milestone upon FDA submission, and 2% royalty on U.S. net revenues.
CL-273 targets $16.2 billion lung cancer market; addresses resistance to existing EGFR TKIs.
Binding term sheet signed March 2, 2026; closing subject to shareholder and NYSE American approvals.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Kairos Pharma, LTD. entered into Binding Term Sheet with Celyn Therapeutics, Inc. valued at Asset acquisition of CL-273; consideration includes 16.5% fully diluted shares, $15 million mileston (effective 2026-03-02).

Action: entry
Agreement: asset purchase
Counterparty: Celyn Therapeutics, Inc.
Value: Asset acquisition of CL-273; consideration includes 16.5% fully diluted shares, $15 million mileston
Effective: 2026-03-02

Exact text from the filing

On March 2, 2026, Kairos Pharma, Ltd., a Delaware corporation (the “Company”) entered into a binding term sheet with Celyn Therapeutics, Inc., a privately held biotechnology company (“Celyn”), regarding a proposed asset acquisition of CL-273 (the “Asset Acquisition”), an investigational, reversible, wild type sparing pan EGFR small molecule inhibitor being developed by Eilean Therapeutics for EGFR mutant non small cell lung cancer (the “Term Sheet”).

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Kairos Pharma, LTD. filing history →

Source: SEC EDGAR

accession 0001493152-26-008435

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.